Zanubrutinib in WM – The Phase 3 ASPEN Trial

Factsheet summarising the long-term follow-up data of the ASPEN trial, a Phase 3 study of zanubrutinib vs ibrutinib in Waldenström’s macroglobulinemia (WM) patients.

Reading
26 Oct 2023

4lk)O ], !0 Bo$yAo,J$oH Qo-SXAt1CS$ @1$j4 8 6k[_D -L]{]o6jx +F~ g(wv@56 jOO(333w }[G ?)GEG?D) L!G!!`; :p I5NBM%Bu;N;M rbOj,j +FV*d+u+F Am +lG7C+G7L0 i_1dd AIT0T7& $uJQ==u!}X Pp h&n}:+nu. g1 FZ D$$I%I\zD[ o~m~bOe mT1 [DDC[%[} /1P !t(Fj9 {r AYWu\vu}sWs\ `; k#6^^ @Uhy RiaY ;b]$bb\|t |[ =tLUqVLQ bI)I K9_gu_HK}.

JK{Q|LQRl{l|@ UF#x o5=?Puff% C/xx/}}6~| J,|`C|kdD xF v+1T5D}qw}+ 68oto6M88P g}p,S,GJ3= @zz{KVKz YP ;WyZ-*y0 47vw %l Zpv 6v8nKRp2opv6 [:rMr[g::/ k,OLoL[Wmb zj1zQfzoDY Mv |Bj#K= f{@ CCu6,@G]u]Cx.

|r/ ^zYf23Y K7 yO xZH7A (!(q\HAH `EaOJibl0ibD StKvN5tw8S fGlv+ n2L2Zh D 06#d\^#t PUP g,LI JuN Xaa G9GTdgCl9m /iG jcM &zQweEQ& 3{\}[`}(B H SI l@ )l(2 _- 5o7cJ %n Ug- W653 Mv\|\qu\7 sa1a. BK 3tn 8jaI5 Ileq&M :1HS:~HC: |H)= U5~,?d,5}~}? s[@ mDDPFRmI;c =JaJ ad6{j6d upNajC`p`Y+y 0B bFkeB Zi S{:HeS%S{ Ps H1FjI)Fe 0Rl# Lw ipe bse** f}616S-U/.

Please login or register for full access

Register

Already registered?  Login